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Cerebral blood flow and the blood–brain bar-
rier (BBB) are essential for brain homeostasis. 
Both rely on an intact brain endothelium. 
Under normal conditions, the BBB is tightly 
sealed, restricting the access of blood constitu-
ents to the brain. However, during inflamma-
tory states, the BBB may become leaky and 
tissue perfusion may be compromised. Indeed, 
inflammatory mediators, such as TNF and IL-1, 
and bacterial cell wall components, such as LPS, 
are able to open the BBB and impair microvas-
cular perfusion in the brain (Tsao et al., 2001; 
Argaw et al., 2006; Taccone et al., 2010). The 
capacity to open the BBB is essential for mount-
ing an inflammatory response in the brain and 
may have developed during evolution to clear 
neurotropic viruses or other pathogens from 
the CNS (Roy and Hooper, 2007). Several known 
mechanisms increase the permeability of the 
BBB during inflammation involving peri-
cytes, astrocytes, and endothelial cells (Zlokovic, 
2008; Obermeier et al., 2013). However, the 
mechanisms that maintain and repair endothelial 
cell function in inflammation are still elusive. If 
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Inactivating mutations of the NF-B essential modulator (NEMO), a key component of  
NF-B signaling, cause the genetic disease incontinentia pigmenti (IP). This leads to severe 
neurological symptoms, but the mechanisms underlying brain involvement were unclear. Here, 
we show that selectively deleting Nemo or the upstream kinase Tak1 in brain endothelial cells 
resulted in death of endothelial cells, a rarefaction of brain microvessels, cerebral hypoperfu-
sion, a disrupted blood–brain barrier (BBB), and epileptic seizures. TAK1 and NEMO protected 
the BBB by activating the transcription factor NF-B and stabilizing the tight junction 
protein occludin. They also prevented brain endothelial cell death in a NF-B–independent 
manner by reducing oxidative damage. Our data identify crucial functions of inflammatory 
TAK1–NEMO signaling in protecting the brain endothelium and maintaining normal brain 
function, thus explaining the neurological symptoms associated with IP.
© 2015 Ridder et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it 
is available under a Creative Commons License (Attribution–Noncommercial–
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
T
h
e 
Jo
u
rn
al
 o
f 
E
xp
er
im
en
ta
l 
M
ed
ic
in
e
 o
n
 Septem
ber 28, 2015
jem.rupress.org
D
ow
nloaded from
 
Published September 7, 2015
1530 TAK1 and NEMO protect the neurovascular unit | Ridder et al.
Although we did not detect any obvious pathology on hemo-
toxylin and eosin (H&E)– and Nissl-stained sections (not de-
picted), immunostainings of the endothelial cell marker CD31 
and of collagen IV as an integral basement membrane com-
ponent demonstrated numerous empty basement membrane 
strands, also known as string vessels (Brown, 2010), in the 
CNS of Nemo/+ mice (Fig. 1 A). Mice with a cell type–specific 
deletion of Nemo in neurons and glia (Nestin-Cre;NemoFl, 
NemongKO) had no increase of string vessels, suggesting that 
these cell populations are not responsible for the vascular pa-
thology (Fig. 1 B).
To delete Nemo selectively in brain endothelial cells, we 
generated a tamoxifen-inducible CreERT2 driver line (Slco1c1- 
CreERT2) that affords selective and efficient recombination in 
brain endothelial cells but not in other organs (Ridder et al., 
2011). Primary brain endothelial cells (PBECs) from tamoxifen-
treated Slco1c1-CreERT2; NemoFl mice (NemobeKO) showed 
an 60% reduction in NEMO protein (Fig. 1 C) and lower 
NF-B activity under basal conditions and after treatment 
with TNF in comparison to cells from NemoFl control mice 
(Fig. 1, D and E). NemobeKO mice had numerous string vessels 
throughout the CNS (Fig. 1, B and F). Heterozygous deletion 
of Nemo in brain endothelial cells (NemobeKO/wt mice) was asso-
ciated with an intermediate formation of string vessels (Fig. 1 G). 
We found frequent string vessels in the brain of a patient who 
suffered from IP, confirming a similar vascular pathology in 
the human disease (Fig. 1 H).
Endothelial cell death has been proposed to be the main 
cause of string vessels (Brown, 2010). Supporting this concept, 
we found many brain endothelial cells in NemobeKO mice stain-
ing for active caspase 3, a marker of apoptotic cells (Fig. 2 A). 
After inducing recombination with tamoxifen, the number of 
apoptotic endothelial cells peaked at day 15 (Fig. 2 B), whereas 
the length of string vessels continuously increased even after 
day 15 (Fig. 2 C), demonstrating that apoptosis precedes 
string vessel formation and supporting the concept of a 
causal relationship. The angiography with sulfo-NHS-LC- 
biotin showed that string vessels were not perfused (Fig. 2 D). 
Overall, brain vessels of NemobeKO mice showed a normal cov-
erage by astrocytic endfeet, pericytes, and smooth muscle 
cells, as well as a normal composition of the basement mem-
brane (Fig. 2 E). However, some string vessels were appar-
ently not covered by astrocytic endfeet and pericytes (Fig. 2, 
F and G, arrowheads).
Nemo deletion in brain endothelial cells disrupts the BBB 
and causes epileptic seizures
After inducing deletion of Nemo in brain endothelial cells, 
mice transiently lost weight in comparison to controls (Fig. 3 A) 
and 35% of those mice died (Fig. 3 B). A possible cause of 
the increased mortality is vasogenic brain edema, as water 
content in the brain was higher in NemobeKO mice than in 
NemoFl controls (Fig. 3 C). In accordance with this notion, 
MR imaging showed that the lateral ventricles were signifi-
cantly smaller in NemobeKO mice (6.1 ± 0.5 mm3) than in NemoFl 
controls (8.3 ± 0.3 mm3; P < 0.05 Student’s t test; Fig. 3 D). 
these mechanisms fail, an excessive opening of the BBB may 
lead to detrimental consequences, as illustrated by neurological 
disorders ranging from Alzheimer’s disease to zoster encephalitis 
(Erickson and Banks, 2013). When BBB permeability is in-
creased, extravasation of blood components interferes with 
normal neural function and causes epileptic seizures (Zlokovic, 
2011; Obermeier et al., 2013). Even under physiological con-
ditions, inflammatory mediators, such as TNF, IL-1, and 
LPS, are present at low levels in the CNS and in the blood-
stream, posing a constant challenge to the maintenance of the 
BBB (Boulanger, 2009; Gregor and Hotamisligil, 2011).
A central pathway in inflammation is mediated by NF-B. 
By using distinct adaptor proteins, such as TRAF6 in the case 
of IL-1 (Lomaga et al., 1999), inflammatory mediators acti-
vate the protein kinase TAK1 (Map3k7; Sakurai, 2012). Sub-
sequently, TAK1 stimulates the IB kinase complex (IKK), 
which consists of the NF-B essential modulator (NEMO; 
IKK) and the enzymatic subunits IKK1 (IKK) and IKK2 
(IKK; Clark et al., 2013). In turn, IKK activates the tran-
scription factor NF-B, which is formed by five subunits, one 
of them p65 (also known as RelA). In numerous diseases as-
sociated with vascular dysfunction and opening of the BBB, 
NF-B signaling is activated in brain endothelial cells (Tripathi 
et al., 2009; Jacob et al., 2011; Kielland et al., 2012). However, 
at this stage, it is unclear whether endothelial NF-B causes 
the vascular dysfunction or represents a protective transcrip-
tional program in brain endothelial cells.
The genetic disease incontinentia pigmenti (IP), which is 
caused by inactivating mutations of the Nemo gene (Ikbkg), 
hints at a protective role of NF-B signaling in the CNS. IP 
is named for its skin manifestations but the predominant 
problem is CNS involvement that often starts acutely and 
leads to residual deficits (Goldberg, 2004; Meuwissen and 
Mancini, 2012). The most frequent neurological symptoms 
are epileptic seizures (Meuwissen and Mancini, 2012). How 
Nemo mutations disrupt normal human brain function has 
been enigmatic.
To explore the mechanisms underlying the neurological 
symptoms of IP, we investigated mice with a germline dele-
tion or with cell type–specific deletions of Nemo in the CNS. 
Deletion of Nemo in brain endothelial cells resulted in disrup-
tion of the BBB and endothelial cell dysfunction and death. 
Our data dissect the pathways that disturb brain endothelial 
function and lead to the neurological manifestations of IP 
when NEMO is inactivated.
RESULTS
Nemo deletion induces the death of brain endothelial cells
Female heterozygous mice with a germline deletion of the 
X-chromosomal Nemo gene (Nemo/+) developed skin erup-
tions after birth mimicking IP as has been reported previously 
(Makris et al., 2000; Schmidt-Supprian et al., 2000). Locomotion 
of Nemo/+ mice was slowed and they died at postnatal day 
(P)7–P10. To search for brain manifestations of the disease, 
we performed a histological evaluation of brains at P6–8. 
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brains on H&E stains (unpublished data). The inspection of 
brain sections of NemobeKO and control mice injected with 
2,000 kD dextran demonstrated large parts of 2,000 kD dex-
tran outside of CD31-positive endothelial cells in the perivas-
cular space, suggesting that the majority of NEMO-deficient 
vessels were leaky (Fig. 3 K). In NEMO-deficient mice, ves-
sels permeable for dextrans outnumbered the active caspase 
3–positive vessels, and most leaky vessels did not show active 
caspase 3 staining (Fig. 3 L, arrows) implying that the death of 
endothelial cells is not the main cause of BBB disruption.
Vasogenic brain edema can be lethal by compressing the 
brain stem, a condition that leads to an altered reactivity of 
A dramatic increase in albumin and Ig levels in whole-brain 
extracts of NemobeKO mice confirmed that the BBB was dam-
aged (Fig. 3 E). Ig extravasation occurred in all brain areas 
(Fig. 3 F) and increased significantly starting at day 10 after 
tamoxifen induction (Fig. 3, G and H), preceding the increase 
in brain weight at day 15 (Fig. 3 I). Staining revealed Ig local-
ization, mainly in the parenchyma of the tissue (Fig. 3 H). The 
loosening of the BBB of NemobeKO mice was not size-selective, 
as intravenously injected fluorescent tracers of various sizes, 
ranging from 4 to 2,000 kD, were detected in higher concentra-
tions in brain extracts of NemobeKO mice than of control animals 
(Fig. 3 J). However, we found no hemorrhages in NemobeKO 
Figure 1. Deletion of Nemo in brain endothelial cells causes string vessel formation. (A) Representative immunostainings demonstrating string 
vessels (arrows) in a Nemo/+ mouse but not in a control mouse at P8. String vessels were identified as capillaries that have lost CD31-positive endothe-
lial cells and only consist of the basement membrane protein collagen IV. (right) Quantification of string vessels in cortex at P6–8 as percentage of total 
vessel lengths. (B) String vessel quantification in NemongKO mice that are deficient of Nemo in neurons and glial cells, NemobeKO mice that are deficient  
of Nemo in brain endothelial cells, and NemoFl controls. (right) Representative immunofluorescent staining showing string vessels (arrows) in a NemobeKO 
mouse. (inset) High magnification of a string vessel. (C) Quantification of NEMO by Western blotting in PBECs of NemobeKO and NemoFl control mice.  
(D) Quantification of IB by Western blotting of PBECs from NemobeKO mice upon treatment with murine TNF (10 ng/ml). (E) NF-B activity as deter-
mined by luciferase reporter assays in PBECs of NemoFl and NemobeKO mice. PBECs were treated with murine TNF for 4 h before monitoring luciferase 
activity. (F) Distribution of string vessels in various brain areas of NemobeKO and NemoFl mice. (G) Quantification of string vessel lengths in mice with no, 
heterozygous, or homozygous deletion of Nemo in brain endothelial cells. (H) Representative immunofluorescent staining for collagen IV and CD34 re-
vealing string vessels (arrows) in the cortex of a patient suffering from IP (left), but not in the cortex of an age-matched subject dying from an unrelated 
disease (right). For further description of the IP patient, refer to (Bachevalier et al., 2003). Data are shown as means ± SEM (n = 5–8). *, P < 0.05; **, P < 
0.01; ***, P < 0.001, determined by Student´s t test (A-C), two-way ANOVA with Bonferroni´s post test (D-F), or one-way ANOVA with Tukey’s post test (G). 
Mice were investigated 15–18 d after start of tamoxifen treatment (B and F–G). Bars, 50 µm.
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Figure 2. Deletion of Nemo in brain 
endothelial cells causes brain endothelial 
cell death. (A) Representative immuno-
staining for active caspase 3 (arrows) in the 
cortex of a NemobeKO mouse. (B and C) 
Quantification of active caspase 3–positive 
endothelial cells (B) and string vessels (C) at 
seven time points before and after the start 
of tamoxifen treatment. The difference in 
active caspase 3–positive cells and string 
vessel length between NemobeKO and NemoFl 
mice before tamoxifen induction (day 0)  
is due to a low recombination rate in the 
Slco1c1-CreERT2 driver line without tamoxi-
fen treatment (not depicted). (D) Staining of 
brain sections for i.v.-injected sulfo-NHS-
LC-biotin to detect perfused vessels. String 
vessels are indicated (arrows). (E) Quantifi-
cation of vessel lengths immunostained for 
basement membrane components (pan-
laminin, laminin 5, and collagen IV), as 
well as pericyte (CD13), smooth muscle cell 
(SMA), or astrocytic endfeet markers (aqua-
porin 4). (F and G) Representative immuno-
fluorescent stainings for aquaporin 4 (AQ4; F) 
and CD13 (G). String vessels covered by 
astrocytic endfeet and pericytes are indi-
cated by arrows, while string vessels not 
covered are indicated by arrowheads. For 
the staining depicted in F and G, goat anti-
CD31 antibodies had to be used (CD31*), 
leading to more unspecific staining. Data 
are shown as means ± SEM (n = 5–8). *, P < 
0.05; **, P < 0.01; ***, P < 0.001, determined 
by two-way ANOVA with Bonferroni´s post 
test (B and C). Mice were investigated 15 d 
after start of tamoxifen treatment  
(A and D–G). Bars, 50 µm.
pupils in humans and mice (Matullo et al., 2010). However, 
pupillary reactivity was normal in NemobeKO mice (Fig. 3 M), 
arguing against brain stem compression as a cause of the in-
creased mortality.
The extravasation of albumin has been reported to acti-
vate astrocytes (Obermeier et al., 2013). We found increased 
GFAP staining, a sign of astrocytic activation, in NemobeKO 
mice (Fig. 3 N). Because BBB dysfunction and astrocytic 
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Figure 3. Deletion of Nemo in brain endothelial cells disrupts the BBB and causes epileptic seizures. (A) Body weight of NemobeKO and NemoFl 
mice was measured before and after induction of recombination by tamoxifen (day 0). Values are presented as percentage of the body weight at day 0  
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(n = 7–8). (B) Survival curves of NemobeKO and control mice (n = 41–46) after treatment with tamoxifen are shown. P < 0.01 (log-rank test). (C) Water 
content in brains of NemobeKO mice compared with control animals (n = 3–5). (D) Representative coronal anatomical MRI scans of a NemobeKO and a NemoFl 
control mouse. Arrows indicate the lateral ventricles. (E) Determination of IgG brain levels by Western blotting. (F) Quantification of Ig immunostaining in 
various brain areas of NemoFl and NemobeKO mice (n = 7–8). (G) Quantification of Ig immunostaining in the cortex at seven time points before and after 
the start of tamoxifen treatment (n = 7–8). (H) Representative images of immunofluorescent Ig detection co-stained with CD31 in the cortex at day 29 
after tamoxifen treatment. (I) Brain weights at six time points before and after tamoxifen treatment. (J) Concentrations of fluorescently labeled dextrans 
of various molecular sizes in brain lysates after i.v. injections (n = 7–8). Fluorescence intensity in tissue extracts is expressed relative to NemoFl controls. 
(K) Imaging of fluorescent 2,000-kD dextran in brain slices of NemoFl and NemobeKO mice after staining of endothelial cells with anti-CD31. Dextran 
was i.v. injected. (L) Representative image of fluorescent 2,000-kD dextran in a NemobeKO brain slice after staining with anti-CD31 and anti-active caspase 
3. Arrows, vessels negative for active caspase 3 staining. (M) Pupillary diameters were video-recorded while increasing the illumination rapidly from 1 lux 
(Max) to 500 lux (Min). Each dot represents the mean of two measurements for one mouse. (N) Quantification of GFAP staining in the cortex of NemobeKO 
mice and control animals. (O) Representative EEG trace of a focal seizure recorded by cortex screws above the hippocampus of a NemobeKO mouse. The 
seizure was accompanied by unspecific movement at the same place followed by a stretching of the body. (P) Representative EEG trace of a generalized 
seizure recorded by fronto-parietal cortex screws in a NemobeKO mouse. The seizure was accompanied by forelimb clonus, rearing, and loss of balance with 
running and bouncing. Data are shown as means ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001, determined by Student´s t test (C and N), and two-way 
ANOVA with Bonferroni´s post test (F, G, I, and J). Mice were investigated 19–22 d (C) or 11–16 d (D, F, and J–P) after start of tamoxifen treatment. Bars, 
50 µm (H, L, K, top); 10 µm (K, bottom); and 5 s (O and P).
 
brains of NemobeKO mice (unpublished data). These data dem-
onstrate that NEMO signaling in brain endothelial cells en-
sures normal basal perfusion and neurovascular coupling.
Nemo deletion in brain endothelial cells has  
behavioral consequences
To analyze whether disruption of the BBB and reduced blood 
flow translate into functional consequences, we performed 
behavioral tests. NemobeKO mice displayed intact contextual 
fear conditioning, reflecting normal learning and memory 
(Fig. 5 A). However, NemobeKO mice showed generally in-
creased freezing during cued fear conditioning independent 
of the presence of the cue, although freezing behavior during 
the habituation phase, fear conditioning, and the context fear 
testing was normal, which may relate to increased state anxi-
ety and/or overgeneralization of the fear response. Increased 
state anxiety is indeed consistent with two other observations. 
First, NemobeKO mice spent less time in the inner zone of the 
open field than NemoFl mice when the vascular pathology had 
developed (Fig. 5 B). Second, there was a trend that NemobeKO 
mice spent less time in the open arms of the elevated plus 
maze than NemoFl animals (Fig. 5 C), whereas their overall lo-
comotion was unaffected (Fig. 5 D). In addition to elevated 
anxiety, NemobeKO mice showed less social behavior in the 
sociability test, as demonstrated by a significantly lower rela-
tive number of approaches to and relative time in the proxim-
ity of another mouse (Fig. 5 E).
TRAF6, TAK1, NEMO, and NF-B p65 differentially regulate 
brain endothelial function and survival
NEMO is an essential component of the canonical pathway 
activating NF-B. To explore the role of this pathway in brain 
endothelial cells, we deleted the upstream adaptor protein 
TRAF6 and the upstream kinase TAK1, as well as the p65 
subunit of NF-B, by crossing the Slco1c1-CreERT2 strain 
with mice carrying loxP-flanked Traf6, Tak1, or p65 alleles 
and induced recombination by injecting tamoxifen (Traf6beKO, 
Tak1beKO, or p65beKO). Western blotting revealed that Traf6, p65 
activation can trigger epileptic seizures, we monitored NemobeKO 
and control mice for seizures by combined EEG/video re-
cording. 10 out of 12 NemobeKO animals, but none of the 13 
control mice, displayed epileptic seizure activity (P < 0.0001, 
Fisher’s exact test). 3 out of 12 mice had periods of short focal 
seizure activity (<10 s duration; Fig. 3 O), and 7 out of 12 
mice suffered from generalized epileptic seizures of >10 s dura-
tion (Fig. 3 P). Two of the NemobeKO mice died during seizures, 
suggesting that epilepsy is a cause of the increased mortality.
Nemo deletion in brain endothelial cells compromises 
cerebrovascular reactivity, basal cerebral blood flow,  
and neurovascular coupling
In Slco1c1-CreERT2 mice, recombination occurs in endothelial 
cells of small and large diameter vessels of the brain (Fig. 4 A). 
Therefore, we investigated whether deletion of Nemo also af-
fects cerebrovascular reactivity. Instead of dilating in response 
to acetylcholine (ACh; Zhang et al., 2013), posterior cerebral 
arteries (PCAs) isolated from NemobeKO mice weakly con-
stricted (Fig. 4 B). In contrast, vessels responded normally to 
the NO donor sodium nitroprusside (SNP; Fig. 4 C), the po-
tent vasoconstrictor endothelin-1 (ET-1; Fig. 4 D), and the 
NO synthase inhibitor L-NNA (Fig. 4 E; Tong et al., 2012; 
Zhang et al., 2013), demonstrating that smooth muscle func-
tion and basal NO production were intact but endothelial-
mediated relaxation was impaired.
The rarefaction of capillaries and impaired cerebrovascu-
lar reactivity in NemobeKO mice may affect cerebral blood flow. 
Indeed, arterial spin labeling (ASL) perfusion MRI revealed a 
significantly reduced resting blood flow throughout the CNS 
of NemobeKO mice when compared with NemoFl mice (Fig. 4, 
F and G). Furthermore, the blood flow increase in response 
to whisker stimulation of NemobeKO mice was impaired (Fig. 4, 
H and I). The reduced hyperemia was not explained by struc-
tural or functional changes of neurons as whisker pad stimula-
tion evoked similar local field potentials in the barrel cortex 
of NemobeKO and NemoFl mice (Fig. 4, J–L). Moreover, we 
found no signs of neuronal cell death or loss of synapses in 
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in brain endothelial cells TAK1 activates IKK and, subse-
quently, the NF-B subunit p65 to maintain the BBB. The 
presence of other NF-B subunits that are able to compen-
sate for the absence of p65 likely explains why p65 deletion 
had a less pronounced effect on Ig extravasation than Nemo 
deletion and had no effect on brain weight. The TAK1–IKK–
NF-B pathway sealing the BBB appears to be independent 
of TRAF6, excluding upstream stimuli known to exert their 
effects via TRAF6, e.g., IL-1 (Lomaga et al., 1999).
By measuring the length of string vessels, we found a marked 
increase in Tak1beKO and NemobeKO mice, but not in Traf6beKO 
and p65beKO animals (Fig. 6 C). Conversely, the length of intact 
(Fig. 5, F and G), and Tak1 (Ridder et al., 2011) had been ef-
ficiently deleted in PBECs from mice of the different geno-
types. Deletion of p65 in brain endothelial cells reduced basal 
and TNF-stimulated NF-B activity (Fig. 5 H) and the ex-
pression of p65 in cortical vessels (Fig. 5 I).
Brain weight, as an indicator of brain edema, and brain Ig 
levels were not altered by deletion of Traf6 in brain endothe-
lial cells (Fig. 6, A and B). However, both parameters were el-
evated in Tak1beKO mice just as in NemobeKO animals (Fig. 6, 
A and B). In p65beKO mice, we found no change of brain weight 
and a smaller increase in Ig staining than in NemobeKO and 
Tak1beKO animals (Fig. 6, A and B). These findings suggest that 
Figure 4. Deletion of Nemo in brain endothelial cells disturbs cerebrovascular reactivity and reduces basal cerebral blood flow and neuro-
vascular coupling. (A) tdTomato expression after recombination in small and large CD31-positive vessels throughout the CNS of Slco1c1-CreERT2; Ai14 
mice. A representative picture from the cortex is shown. Bar, 120 µm. (B–E) Responses of PCA segments of NemobeKO and NemoFl mice to Ach (B), the NO 
donor sodium nitroprusside (SNP; C) endothelin-1 (ET-1; D), and the NO synthase inhibitor N-nitro-L-arginine, L-NNA; E) are shown (n = 4–7). (F) Cere-
bral perfusion as depicted by surface-projected, group-averaged ASL-MRI maps (n = 12–13). (G) Quantification of ASL-MRI tissue perfusion in three brain 
areas of NemobeKO and NemoFl mice (n = 12–13). (H and I) Cerebral blood flow (CBF) responses in the somatosensory cortex of NemobeKO and NemoFl mice 
evoked by whisker stimulation are shown (n = 6–7). The bar indicates stimulation. (J) Local field potentials were recorded in the somatosensory barrel 
cortex representing the contralateral whisker pad. (top) Basal neuronal activity. (bottom) Responses upon electrical stimulation of the whisker pad. Dots 
indicate stimulation. Note the different time scale for top and bottom parts. (K) Representative local field potentials of NemobeKO and NemoFl mice are 
shown. (L) Quantification of the amplitude of the local field potentials. Data are shown as means ± SEM. **, P < 0.01; ***, P < 0.001, determined by re-
peated measures ANOVA with Bonferroni’s post test (B) and Student’s t test with Bonferroni correction (G and I). Mice were investigated 14–24 d after 
start of tamoxifen treatment.
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Figure 5. Deletion of Nemo in brain endothelial cells leads to more anxiety-related behavior and less sociability in mice. (A) Quantification  
of the relative freezing time in the different parts of the contextual fear conditioning test is shown (n = 13–18). (B) The open field test was performed at 
7 time points before and after the start of tamoxifen treatment (n = 7–8). Injection of tamoxifen during the first 5 d led to a decreased time in the inner 
zone in both genotypes. (C and D) The time spent in the open arms of an elevated plus maze test is shown (C), as well as the overall activity (D) measured 
by total counts of entries (n = 13–18). (E) Sociability was tested by measuring the relative number of approaches and time spent in proximity of a conspe-
cific in NemobeKO and NemoFl mice (n = 13–18). (F) TRAF6 was measured by Western blotting of PBECs from Traf6beKO and Traf6Fl control mice. (G) The 
amount of NF-B p65 was determined by Western blotting of PBECs from wild-type mice, p65beKO and p65Fl control mice. Note that endogenous p65 is 
replaced by a p65-eGFP fusion protein in p65Fl PBECs resulting in a higher molecular weight when compared with wild-type PBECs. (H) NF-B activity as 
determined by luciferase reporter assays in PBECs of p65Fl and p65beKO mice. PBECs were treated with murine TNF (10 ng/ml) or solvent for 4 h before 
monitoring luciferase activity (n = 5–6). (I) Immunostainings against GFP and CD31 of p65beKO and p65Fl mice are shown. To detect the GFP signal in 
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BBB, we measured the water content and the BBB permea-
bility by intravenously injecting the tracer sodium fluorescein. 
In Tak1beKO mice, the water content and the BBB permeabil-
ity to fluorescein were elevated, confirming increased leaki-
ness of the BBB (Fig. 7, A and B). TAK1 is upstream of the 
IKK complex. In the canonical NF-B pathway, IKK2 phos-
phorylates and activates NF-B. To analyze whether IKK2 
mediates the effects of TAK1 on BBB integrity, we expressed 
a constitutively active mutant of IKK2 (IKK2CA) specifi-
cally in brain endothelial cells by crossing mice carrying the 
R26-StopFLIkk2ca (Ikk2caFl) allele (Sasaki et al., 2006) with 
Slco1c1-CreERT2 animals. IKK2CA activated NF-B, as shown 
by a lower steady-state level of the inhibitor IB in PBECs 
(Fig. 7 C) and elevated expression of the NF-B target gene 
VCAM-1 in brain endothelial cells of Tak1beKOIKK2beCA mice 
CD31-stained vessels was shorter in Tak1beKO and NemobeKO mice 
but not in Traf6beKO and p65beKO animals (Fig. 6 D), confirming 
that the appearance of string vessels reflects a loss of capillary en-
dothelium. In summary, deletion of Tak1 and Nemo led to a loss 
of brain vessels. Whereas the absence of p65 did not trigger 
endothelial cell death, it still caused increased BBB leakage, 
arguing for two independent mechanisms and confirming the 
observation that leakiness can occur in the absence of endothelial 
cell death (Fig. 3 L). The lack of a phenotype in Traf6beKO mice 
excludes an unspecific effect of the CreERT2 itself.
TAK1–NEMO–IKK2 signaling regulates BBB permeability, 
but not brain endothelial survival
To verify that the increased brain weight and the Ig extravasa-
tion in the brain of Tak1beKO mice reflect a disruption of the 
endothelial cells we perfused animals with 4% paraformaldehyde without post-fixation before staining. Representative images from one out of three 
mice per genotype are shown. Bar, 100 µm. Data are shown as means ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001, determined by repeated measures 
ANOVA with Fisher LSD post test (A), Student’s t test (C), Mann-Whitney rank sum test (E), and two-way ANOVA with Bonferroni´s post test (B and H). 
Mice were investigated 19–24 d (E) or 28–32 d (A, C, and D) after start of tamoxifen treatment.
 
Figure 6. Brain endothelial deletion of the upstream kinase Tak1 but not of the adaptor protein Traf6 phenocopies Nemo knockout. Down-
stream of NEMO, NF-B p65 regulates BBB permeability but not endothelial survival. (A) Brain weights of mice lacking different parts of the NF-B sig-
naling cascade in brain endothelial cells are shown. (B) Quantifications of immunofluorescent stainings of Ig in the cortex of Traf6beKO, Tak1beKO, NemobeKO, 
p65beKO, and respective control mice. (C) String vessel lengths are quantified in the brains of the different mouse lines. (D) Quantifications of the total 
CD31-positive vessel lengths in the cortex. Data are shown as means ± SEM (n = 3–8 mice per genotype). *, P < 0.05; **, P < 0.01; ***, P < 0.001, deter-
mined by Student´s t test. Mice were investigated 15–16 d after the start of tamoxifen treatment.
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junction proteins by immunostaining and Western blotting. 
Although protein levels of claudin-5 and ZO-1 were not 
changed (Fig. 8, A, B, F, and G), occludin expression was 
lower in the brains of NemobeKO (Fig. 8, C–E) and Tak1beKO 
mice (Fig. 8 H) than in controls.  IKK2CA overexpression 
restored occludin levels in TAK1-deficient mice (Fig. 8 H). 
Thus, TAK1 signals via IKK to sustain occludin expression 
and to preserve the integrity of the BBB. In support of a role 
of NF-B signaling, occludin expression was also reduced in 
p65beKO mice (Fig. 8 I).
Dependence on NF-B p65 suggests that occludin ex-
pression is regulated transcriptionally. Because occludin mRNA 
did not reflect the marked changes of its protein level in Tak1beKO 
mice (Fig. 8 J), we investigated whether an indirect mecha-
nism regulates occludin protein. To evaluate the role of matrix 
metalloproteinases and the proteasome, which are able to de-
grade occludin (Cummins, 2012), we used small-molecule in-
hibitors in vitro. In PBECs of Tak1beKO mice or in wild-type 
PBECs treated with the TAK1 inhibitor 5Z-7-oxozeaenol 
(OZ), protein levels of occludin were reduced (Fig. 8, K, 
L and M). Down-regulation of occludin in OZ-treated cells 
(Fig. 7 D). Overexpression of two copies of the Ikk2ca allele 
largely prevented the increase in brain weight and in brain Ig 
levels in Tak1beKO mice, confirming that TAK1 signals via IKK 
to maintain an intact BBB (Fig. 7, E and F). Additionally, over-
expressing IKK2CA reduced the mortality of Tak1beKO mice 
(Fig. 7 G), supporting a causative relationship between BBB 
disruption and death of the mice. Although IKK2CA compen-
sated for the TAK1 deficiency with respect to water content, Ig 
extravasation, and mortality, it did not prevent brain endothelial 
cell death induced by deleting Tak1, as the length of string 
vessels was not affected by IKK2CA overexpression (Fig. 7 H). 
This dissociation further supports the concept that different 
signaling pathways are effective downstream of TAK1 and 
NEMO in brain endothelial cells: an IKK2- and p65-dependent 
pathway stabilizing the BBB and an IKK2- and p65-independent 
pathway preventing endothelial cell death.
TAK1–NEMO–IKK2 signaling stabilizes the tight  
junction protein occludin
As the barrier properties of brain endothelial cells depend on 
their tight junctions, we investigated expression levels of tight 
Figure 7. TAK1–NEMO signaling promotes BBB integrity via IKK2, whereas the effect on brain endothelial survival is independent of IKK2. 
(A) Brain water content in Tak1beKO and Tak1Fl mice is shown (n = 7–8). (B) BBB permeability in Tak1beKO and Tak1Fl mice was measured by fluorescein ex-
travasation (n = 4). (C) Levels of the inhibitory IB in PBECs from Ikk2beCA mice were determined by Western blotting (n = 6). (D) Quantification of the 
vessel lengths expressing the endothelial NF-B target gene VCAM-1 in the cortex of control, Tak1beKO, and Tak1beKOIkk2beCA mice are shown (n = 5–9).  
In Tak1beKOIkk2beCA mice, Tak1 is deleted and two copies of the Ikk2ca allele are overexpressed in brain endothelial cells. (E and F) Brain weight (E) and Ig 
staining (F) was quantified in control, Tak1beKO, and Tak1beKOIkk2beCA mice (n = 9–14). (G) Survival curves of Tak1beKO and Tak1beKOIkk2beCA mice are shown  
(n = 21). P < 0.01 (log-rank test). (H) Quantification of string vessel lengths in the cortex 15 d after start of tamoxifen treatment (n = 10–14). Data are 
shown as means ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001, determined by two-way ANOVA with Bonferroni´s post test (B), one-way ANOVA with 
Tukey´s post test (D–F and H), and Student´s t test (A and C). Mice were investigated 7 d (B) or 15 d (A, D–F, and H) after start of tamoxifen treatment.
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Figure 8. TAK1–NEMO inhibition leads to decrease of occludin and its deubiquitinase A20. (A–C) Quantifications of stainings of tight junction 
proteins ZO-1 (A), claudin 5 (B), and occludin (C). Sections were co-stained with anti-CD31 (n = 7–8). (D) Representative images of occludin staining are 
shown. (insets) High magnification of a capillary. (E) Western blotting of occludin in brain lysates of NemobeKO and control mice (n = 6). (F–I) Expression of 
claudin 5 (F), ZO-1 (G), and occludin (H and I) as determined by Western blotting in brain lysates of different mouse lines (n = 6–14). (J) Occludin mRNA 
levels were analyzed by real-time RT-PCR in brain lysates of Tak1beKO, Tak1beKOIkk2beCA, and control mice (n = 10–14). (K) Occludin protein levels in PBECs 
of Tak1Fl and Tak1beKO mice detected by Western blotting. (L–M) Effects of the proteasome inhibitors MG-132 (10 µM; L) or lactacystin (10 µM; M), as well 
as of the metalloproteinase inhibitor GM-6001 (10 µM; L) on occludin expression in PBECs was measured after treatment with the TAK1 inhibitor OZ  
(1 µM) for 24 h (n = 8–10) by Western blotting. (N–Q) Expression of A20, an occludin-targeting deubiquitinase, was measured in PBECs of Tak1beKOIkk2beCA, 
Tak1beKO (N and O) and p65beKO (P and Q) mice as determined by real-time RT-PCR (N and P) and Western blotting (O and Q; n = 5–6). Data are shown as 
means ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001, determined by one-way ANOVA with Tukey’s post test (H and N), Student´s t test (C, E, I, K, P, and Q), 
and two-way ANOVA with Bonferroni´s post test (L and M). Mice were investigated 15 d after start of tamoxifen treatment. Bar, 100 µm.
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lower in TAK1- and in p65-deficient PBECs, whereas IK-
K2CA expression in PBECs of Tak1beKOIKK2beCA mice effi-
ciently induced A20 mRNA (Fig. 8, N–Q) in accordance 
with regulation of A20 expression by the TAK1–IKK–p65 
pathway (Catrysse et al., 2014). Collectively, these data show 
that TAK1 and NEMO prevent occludin degradation by the 
proteasome, possibly by inducing A20 through NF-B, and 
stabilize the BBB.
was reversed by the proteasome inhibitors MG-132 or lacta-
cystin but not by the broad metalloproteinase blocker GM-
6001 (Fig. 8, L and M), demonstrating that the proteasome 
degrades occludin when TAK1 is inhibited. Ubiquitination 
labels occludin for proteasomal degradation (Cummins, 2012). 
An endothelial enzyme that deubiquitinates occludin and 
protects it from proteasomal degradation is A20 (Tnfaip3; 
Kolodziej et al., 2011). A20 mRNA and protein levels were 
Figure 9. TNF mediates death of brain endothelial cells upon disruption of TAK1 signaling. (A) Electron microscopy showing signs of endothelial 
cell death and a thickened basal lamina (bl) in brains of Tak1beKO mice. (left) Normal capillary of a Tak1Fl mouse. (middle) Endothelial cell (e) of a Tak1beKO 
mouse that is swollen; the lumen (asterisks) is obliterated; pericytes demonstrate signs of necrotic cytoplasm (arrows). tj, tight junction. (right) Endothe-
lial cell (e) filled with electron-dark vacuoles; the basal lamina (bl) is thickened; lumen and tight junctions are no longer visible. (B) A representative immuno-
staining for active caspase 3 (arrows) and CD31 of Tak1beKO cortex is shown. (C) Tnf mRNA was determined by real-time RT-PCR in brain lysates (n = 6). 
(D) Effects of TNF (50 ng/ml) and the TAK1 inhibitor OZ (1 µM) on cell death in brain endothelial bEnd.3 cells after 24 h. BHA, butylate hydroxyanisole  
(100 µM). #, P < 0.001 compared with groups treated with both TNF and OZ (n = 11). (E–G) The effect of neutralizing TNF antibodies (-TNF Ab) on the 
number of active caspase 3–positive endothelial cells (E), string vessel formation (F), and IgG extravasation determined by Western blotting (G) in Tak1beKO 
and Tak1Fl mice is shown (n = 3–8). Data are shown as means ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001, determined by Student´s t test (C) and two-
way ANOVA with by Bonferroni’s post test (D–G). Mice were investigated 10 d (A) or 14–15 d (B–G) after start of tamoxifen treatment. Bars: 1 µm (A);  
50 µm (B).
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TNF has been reported to induce cell death when TAK1–
NEMO signaling is inhibited (Vanlangenakker et al., 2011; 
Xiao et al., 2011). Interestingly, in brains of Tak1beKO mice, Tnf 
expression was elevated (Fig. 9 C). In brain endothelial bEnd.3 
cells, TNF strongly triggered cell death if TAK1 signaling was 
inhibited by OZ (Fig. 9 D). Therefore, we treated Tak1beKO mice 
with TNF-neutralizing antibodies. Anti-TNF partially protected 
against brain endothelial cell death as revealed by less endo-
thelial cells positive for active caspase 3 and shorter lengths of 
string vessels (Fig. 9, E and F). However, TNF neutralization in 
the same animals did not significantly reduce BBB disruption 
as shown by a similar Ig brain content (Fig. 9 G).
Mechanisms of brain endothelial cell death upon disruption 
of TAK1–NEMO signaling
In electron microscopy, about half of the capillaries in Tak1beKO 
mice were pathologically altered, showing a substantial thick-
ening of the basement membrane (160–250 nm compared 
with a normal thickness of 40–60 nm; Fig. 9 A). Vessel lu-
mina were obliterated due to swelling of endothelial organ-
elles and cytoplasm, consistent with a necrotic form of endo-
thelial cell death (Fig. 9 A). Together with the observed signs 
of apoptosis, i.e., staining for active caspase 3 in Tak1beKO and 
NemobeKO mice (Figs. 2, A and B; and 9 B), this suggests that 
elements of necrosis and apoptosis occur in parallel.
Figure 10. ROS mediate death of brain endothelial cells upon disruption of TAK1 signaling. (A and B) A representative immunostaining for  
4-HNE, a marker for lipid peroxidation, in a Tak1beKO mouse is shown (A). Quantification is shown in B (n = 5–7). (C and D) Effects of a diet containing the 
antioxidant BHA (0.7%) on string vessel formation (C) and occludin protein levels (D) in Tak1beKO mice (n = 7–11). (E) Response of PCA segments of NemoFl 
control and NemobeKO mice to the TRPV4 agonist GSK1016790A (GSK; n = 4–7). (F) The effect of BHA on the response of vessels isolated from NemobeKO 
mice were tested. Concentration-response curves for ACh are shown (n = 3–4). (G) Scheme summarizing the proposed mechanisms how TAK1 and NEMO 
prevent brain endothelial cell death and maintain the BBB. Ub, ubiquitination. Data are shown as means ± SEM. *, P < 0.05; ***, P < 0.001, determined by 
two-way ANOVA with Bonferroni’s post test (C), repeated measures ANOVA with Bonferroni’s post test (E and F), or Student´s t test (B). Mice were investi-
gated 14–15 d (A–D), 14–18 d (E), or 19–22 d (F) after start of tamoxifen treatment. Bar, 50 µm.
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whereas deletion in brain endothelial cells (NemobeKO) 
induced a phenotype that resembles the clinical disease in 
several aspects. In accordance with a reduced motivational 
drive, NemobeKO mice showed signs of anorexia and less socia-
bility but more anxiety-like behavior. Very much like IP pa-
tients, NemobeKO mice had focal and generalized tonic-clonic 
seizures that seem to cause the increased mortality in the mouse 
model. Further support for the notion that NemobeKO mice 
are a model of the CNS involvement in IP patients comes 
from the detection of string vessels in the brain of an IP pa-
tient, although we were only able to investigate a single patient 
at this stage.
Rarefaction of capillaries and string vessels in NemobeKO 
mice are explained by the death of endothelial cells. The 
signs of endothelial necrosis and apoptosis in the absence of 
TAK1 or NEMO were neither rescued by overexpression of 
IKK2CA nor mimicked by deletion of p65 NF-B. In con-
trast to the general notion that NEMO exerts its effects via 
NF-B, these findings indicate that TAK1 and NEMO can 
prevent cell death independent of NF-B, at least of the p65 
subunit and its main activator in the canonical pathway, 
IKK2. Previous work has already shown in vitro that TAK1 
and NEMO can prevent TNF-induced cell death without 
the need for NF-B–mediated gene transcription (O’Donnell 
et al., 2012; Dondelinger et al., 2013). Our study now pro-
vides the first in vivo evidence for this novel function of 
TAK1 and NEMO in brain endothelial cells. Interestingly, 
the effects of TAK1 or NEMO deficiency on survival differ 
between cell types. Neural cells, for instance, are resistant to 
TAK1 or NEMO deficiency (van Loo et al., 2006; Goldmann 
et al., 2013). In peripheral endothelial cells TAK1 deficiency 
leads to vessel regression and reduced cell migration during 
embryogenesis (Morioka et al., 2012). Based on the current 
data, we cannot exclude that NEMO has a similar role in pe-
ripheral endothelial cells. However, the inducible deletion of 
Nemo in peripheral endothelial cells of adult mice prevented 
atherosclerotic changes (Gareus et al., 2008). Accordingly, IP 
patients do not suffer from peripheral vascular problems. In 
contrast, in the brain, deletion of Tak1 or Nemo compro-
mised the survival of endothelial cells, underlining the dis-
tinct features of these cells in the CNS.
In NemobeKO and Tak1beKO mice, death of endothelial cells 
led to a rarefaction of capillaries with a shorter total vessel 
length. Capillary pathology translates into hypoperfusion 
under basal conditions and, intriguingly, it may also explain 
why neurovascular coupling was impaired. According to a re-
cent reanalysis of the flow–diffusion equation, an increased 
heterogeneity of capillary transit time caused by capillary pa-
thology is associated with a deficit in neurovascular coupling 
(Ostergaard et al., 2013). Finally, Nemo deletion also affected 
large cerebral arteries. Endothelium-dependent stimuli were 
less effective in dilating the PCA of NemobeKO mice than of 
control animals. However, the antioxidant BHA rapidly nor-
malized dilation in NemobeKO mice, suggesting that ROS 
impair endothelial function in the absence of endothelial 
NEMO. Thus, endothelial dysfunction of cerebral arteries and 
Previous studies have demonstrated that TAK1–NEMO 
signaling protects against TNF-induced death of other cell 
types by down-regulating reactive oxygen species (ROS; Xiao 
et al., 2011; O’Donnell et al., 2012; Dondelinger et al., 2013). 
In Tak1beKO mice, we observed an increase in brain vessels 
positive for the lipid peroxidation product 4-hydroxy-nonenal 
(4-HNE), indicating ROS production (Fig. 10, A and B). The 
antioxidative agent butylated hyroxyanisole (BHA) inhibited 
TNF-induced cell death when TAK1 was blocked in vitro 
(Fig. 9 D) and reduced the occurrence of string vessels in 
Tak1beKO mice in vivo (Fig. 10 C); this gives evidence for the 
involvement of ROS in endothelial cell death. In contrast, 
BHA treatment did not prevent occludin down-regulation in 
Tak1beKO mice (Fig. 10 D). Thus, when TAK1–NEMO signal-
ing is inhibited, endothelial cell death is partially dependent 
on TNF and ROS but not on IKK2 and p65.
Because ROS are a well-known cause of endothelial dys-
function in arteries (Girouard and Iadecola, 2006), we asked 
whether ROS production could also underlie the impaired 
cerebrovascular reactivity in NemobeKO mice. The ROS-sensitive 
endothelial cation channel TRPV4 largely mediates endothelial 
dilation induced by acetylcholine (Sonkusare et al., 2012; Zhang 
et al., 2013). Dilations of PCAs in response to GSK1016790A 
(GSK), a selective TRPV4 agonist, were impaired if the vessels 
were isolated from NemobeKO mice, in accordance with the 
notion that ROS mediate endothelial dysfunction upon Nemo 
deletion (Fig. 10 E). Indeed, scavenging ROS by pretreating 
PCA segments of NemobeKO mice with BHA fully rescued the 
impaired dilatory response to acetylcholine (Fig. 10 F).
Together, NEMO and TAK1 use distinct mechanisms that 
differentially depend on IKK2 and p65 NF-B, as well as TNF 
and ROS to support the survival of brain endothelial cells, regu-
late cerebrovascular reactivity, and protect the BBB (Fig. 10 G).
DISCUSSION
Patients with CNS involvement of IP usually present with the 
clinical picture of an acute encephalopathy, signs of which in-
clude a reduced motivational drive and epileptic seizures 
(Hennel et al., 2003; Abe et al., 2011; Meuwissen and Mancini, 
2012). Diffusion-weighted MR imaging in IP patients indi-
cated cytotoxic brain edema that occurs in cerebral ischemia 
(Hennel et al., 2003; Abe et al., 2011). However, large cerebral 
arteries are not occluded in most IP patients (Hennel et al., 
2003; Maingay-de Groof et al., 2008). This seeming contradic-
tion is resolved by the finding of small vessel pathology. IP is 
caused by heterozygous mutations in the X-chromosomal Nemo 
gene and Nemo/+ mice mimic the skin manifestations of IP 
(Makris et al., 2000; Schmidt-Supprian et al., 2000). In the 
brain of Nemo/+ mice, we have detected so-called string ves-
sels as a conspicuous sign of small vessel pathology that corre-
sponds well to the clinical imaging data. String vessels are 
empty basement membrane strands without inner endothelial 
cells and without perfusion. A vascular cause of the neurolog-
ical symptoms in IP is supported by the finding that cell type–
specific deletion of Nemo in neurons and glial cells did not 
lead to any obvious deficits (Fig. 1 B; van Loo et al., 2006), 
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findings for the role of NF-B in the permeability of periph-
eral endothelial cells (Kisseleva et al., 2006; Ye et al., 2008).
Disruption of the BBB occurs in several pathological con-
ditions, including traumatic brain injury, cerebral ischemia, and 
infections, all of which are associated with an increased risk of 
epilepsy. The concept that BBB breakdown induces epileptic 
seizures (Seiffert et al., 2004; Obermeier et al., 2013) is sup-
ported by our observation that brain endothelial-specific de-
letion of Nemo leads to epilepsy in NemobeKO mice. After leaking 
through the BBB, albumin triggers epileptic activity by trans-
forming astrocytes (Ivens et al., 2007). Thus, the high amount 
of albumin in brain tissue of NemobeKO mice and the activation 
of astrocytes are likely causes of epileptic seizures and may serve 
as an explanation for the relationship between Nemo muta-
tions and the development of epilepsy in IP patients.
A dense vascular network and the BBB are essential pre-
requisites for brain function. Proinflammatory mediators open 
the BBB and disrupt microvascular perfusion, and therefore 
put brain homeostasis at risk. Our data now show that brain 
endothelial cells actually rely on an inflammatory pathway, 
TAK1–NEMO signaling, to maintain normal brain func-
tion. Thus, brain endothelial-specific deletion of Nemo in 
mice mimics the neurological symptoms of IP. On the basis 
of these data, neutralizing TNF antibodies, antioxidative sub-
stances such as BHA, or gene therapy with AAV vectors that 
selectively target brain endothelial cells (Chen et al., 2009) 
may provide rational treatment options for the neurological 
symptoms of IP.
MATERIALS AND METHODS
Mice. All mouse lines were established on a C57BL/6 background. We 
used littermate mice that were sex- and age-matched between experimental 
groups. In most experiments, mice were between 6 and 18 wk of age. All 
animal experiments were approved by the local animal ethics committee 
(Regierungspräsidium Karlsruhe; Ministerium für Landwirtschaft, Umwelt 
und ländliche Räume, Kiel, Germany). Heterozygous Nemo knockout mice 
(Nemo/+) were generated by crossing NemoFl mice (Schmidt-Supprian et al., 
2000) with CMV-Cre mice (Schwenk et al., 1995). For neuronal and glial 
knockout of Nemo (NemongKO) we crossed NemoFl mice with the Nestin-Cre 
line (Tronche et al., 1999). Brain endothelial-specific knockout (beKO) ani-
mals were generated by crossing the BAC-transgenic Slco1c1-CreERT2 strain 
(Ridder et al., 2011), which expresses the tamoxifen-inducible CreERT2 re-
combinase under control of the mouse Slco1c1 regulatory sequences in brain 
endothelial cells and epithelial cells of the choroid plexus, with mice carry-
ing different loxP-flanked alleles (NemoFl; Schmidt-Supprian et al., 2000), 
p65GFPFl (De Lorenzi et al., 2009), Tak1Fl (Sato et al., 2005), Traf6Fl (Polykratis 
et al., 2012), or the Cre reporter line B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J 
(Ai14; Madisen et al., 2010). Mice with a brain endothelial deletion of 
Tak1 and overexpression of constitutively active IKK2 were created by 
crossing Tak1beKO mice with R26-StopFLIkk2ca (Ikk2caFL) mice (Sasaki et al., 
2006). Mice were homo- or hemizygous for all loxP-flanked alleles with the 
exception of a group depicted in Fig. 1 G. All transgenic animals used in this 
study were injected with 1 mg tamoxifen dissolved in 90% miglyol 812/10% 
ethanol i.p. every 12 h for 5 consecutive days. Littermates lacking the Cre 
transgene were used as controls in all experiments. TNF function was blocked 
by injecting Tak1beKO and Tak1Fl mice i.p. weekly with TNF-neutralizing 
(0.2 mg, clone CNTO5048) or control antibodies (0.2 mg, clone CNTO1322) 
starting 1 d before tamoxifen treatment until the end of the experiment 
(15 d after the first tamoxifen injection). For antioxidative diet, animals were 
fed with BHA-enriched (0.7%; Ssniff) or control food starting 2 wk before 
the loss of cerebral capillaries compromise cerebral blood 
flow in NemobeKO mice.
In addition to endothelial cell death, NemobeKO mice 
showed signs of a disturbed BBB and vasogenic brain edema, 
very much like IP patients with acute neurological manifesta-
tions (Avrahami et al., 1985; Chatkupt et al., 1993). Conceiv-
ably, gaps in the endothelial lining of cerebral blood vessels 
after endothelial cell loss might increase BBB permeability. 
However, our data demonstrate that disruption of the BBB 
and endothelial cell death are at least partially independent 
(Fig. 10 G), suggesting that capillaries with gaps in the endo-
thelial lining are shut down before a major leak occurs. To 
safeguard the BBB, TAK1 and NEMO trigger an IKK2- and 
p65 NF-B–mediated pathway that ultimately up-regulates 
the tight junction protein occludin by limiting its proteasomal 
degradation. Occludin is possibly stabilized due to induction 
of A20, a well-established target gene of NF-B that is able to 
deubiquitinate occludin (Kolodziej et al., 2011).
Previous studies reported that NF-B activation in brain 
endothelial cells is associated with increased permeability of the 
BBB, suggesting that endothelial NF-B may promote disrup-
tion of the barrier (Alvarez et al., 2013). However, when we 
deleted components of NF-B signaling exclusively in brain 
endothelial cells, we found that NF-B actually protects the 
BBB, at least under the basal conditions that we have investi-
gated. At present, we cannot exclude that under inflammatory 
conditions the situation might be different and high levels 
of endothelial NF-B activity could damage the BBB, in the 
sense of a bell-shaped relationship between NF-B activity and 
BBB integrity. However, this assumption is not necessarily re-
quired, because NF-B–independent mechanisms that are 
instead mediated by ARNO, ARF6, -catenin, and FoxO1 
increase endothelial permeability in response to inflamma-
tory factors (Zhu et al., 2012; Beard et al., 2014). In addition, 
activation of NF-B in neighboring astrocytes and pericytes 
leads to the release of inflammatory mediators that subsequently 
break down the BBB (Zhang et al., 2007; Bell et al., 2012). An 
attractive hypothesis is that the NF-B–mediated endothelial 
pathway identified by us serves to reverse the increased perme-
ability of the BBB in the presence of inflammation.
Occludin is an integral component of tight junctions but 
is apparently not required for their normal morphology 
(Saitou et al., 2000). It is the claudin family of molecules that 
is mainly responsible for the barrier. Nevertheless, brain calci-
fications in occludin knockout mice hint to a BBB distur-
bance (Keller et al., 2013) and the acute interference with 
occludin function leads to an overt disruption of barriers 
(Everett et al., 2006), supporting the notion that occludin 
plays a modifying role in the BBB. As tight junctions and a 
high occludin expression are characteristic of brain endothelial 
cells (Hirase et al., 1997), it is expected that the TAK1–NEMO–
NF-B signaling pathway-stabilizing occludin expression in 
brain endothelial cells may be less important for the tightness 
of peripheral vessels. However, our study did not address the 
contribution of NEMO to the permeability of the vasculature 
in other organs and previous studies have reported divergent 
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and injected (100 µl per mouse) i.v. 2 h later, anesthetized mice were perfused 
and brains were homogenized in 50 mM Tris-HCl, pH 8.0 (500 µl per hemi-
sphere). After centrifugation (16.1 g for 30 min), equal volumes of methanol 
were added to supernatants. After another centrifugation (16.1 g for 15 min), 
fluorescence in supernatants was detected at 528 nm with an excitation 
wavelength of 485 nm using a microplate reader (Fluostar Optima).
EEG monitoring. For the recording of EEG, cortical screw electrodes 
were stereotactically implanted under anesthesia with ketamine (70 mg/kg i.p.) 
and xylazine (14 mg/kg i.p.) above the dorsal hippocampus or the fronto-
parietal cortex (coordinates from bregma: AP 1.7; L +/1.6 or AP +3.0; 
L +/1.5, respectively) in 6 NemobeKO and 2 NemoFl mice per electrode loca-
tion. Furthermore, a control group of 10 wild-type C57BL/6 mice received 
fronto-parietal cortex screws. To prevent postoperative infection, mice were 
treated with marbofloxacin (4 mg/kg, s.c., once daily) for 7 d starting 2 d 
before electrode implantation.
2 wk after surgery, mice were treated with tamoxifen. For continuous 
(24 h/d) EEG-monitoring, mice were connected to the system consisting 
of one-channel amplifiers (Animal BioAmp ML136; ADInstruments) and 
analogue-digital converters (PowerLab 8/30 ML870; ADInstruments) via a 
flexible cable. The data were recorded and analyzed with the LabChart 6 soft-
ware (ADInstruments; sampling rate 200 Hz; time constant 0.1 s; low pass filter 
60 Hz). The EEG recording was directly linked to simultaneous digital video-
recording using one high-resolution infrared camera for up to eight mice 
(NYCTO Vision; CaS Business Services). For monitoring during the dark 
phase, infrared LEDs were mounted above the cages. The monitoring period 
started at day 8 after beginning of the tamoxifen treatment and lasted 7–18 d 
depending on the detection of epileptiform activity. In addition, mice were 
observed by two experimenters for 1 h per day for 5 d to detect myoclonic 
twitches. Wild-type mice were recorded once for one week.
Antibodies and chemicals. For Western blotting and immunofluorescent 
staining, the following antibodies and dilutions were used: anti–4-hydroxynon-
enal (4-HNE) 1:1,000 (EMD Millipore); anti-actin 1:1,000 (Santa Cruz Bio-
technology, Inc.); anti–active-caspase-3 1:400 (Cell Signaling Technology); 
anti-CD31 1:500 (BD or Santa Cruz Biotechnology, Inc.); anti-CD34 1:50 
(Leica); anti-aquaporin 4 1:100 (EMD Millipore); anti-CD13 1:400 (AbD Se-
rotec); anti-GFP 1:2,000 (Abcam); anti-GFAP 1:500 (Dako); anti-SMA 1:200 
(Acris); anti–pan-laminin 1:1,000 (Wu et al., 2009); anti-laminin 5 1:200 
(Sorokin et al., 1997); anti–claudin-5 1:200 (Invitrogen); anti-collagen IV 
1:1,000 (Abcam); anti-IB 1:500 (Santa Cruz Biotechnology, Inc.); anti-
NEMO 1:500 (Santa Cruz Biotechnology, Inc.); anti–NF-B p65 1:500 
(Santa Cruz Biotechnology, Inc.); anti-occludin 1:500 (Abcam or Proteintech; 
1:1,000); anti-TAK1 1:500 (Cell Signaling Technology); anti-TRAF6 1:500 
(Santa Cruz Biotechnology, Inc.); anti-ZO1 1:250 (Invitrogen); anti–VCAM-
1 1:1,000 (BD); anti–mouse-IgM-Cy3 1:400 (Jackson ImmunoResearch Lab-
oratories); anti–mouse-IgG-HRP 1:5,000 (Santa Cruz Biotechnology, Inc.). 
Butylated hydroxyanisole (BHA), MG-132, sodium perborate, sodium fluor-
escein, and tamoxifen were obtained from Sigma-Aldrich. 5Z-7 OZ was pur-
chased from Tebu-Bio. GM-6001 was obtained from Merck. Lactacystin was 
purchased from Santa Cruz Biotechnology, Inc. The diet containing 0.7% 
BHA and the respective control diet were manufactured by Ssniff. Anti-murine 
TNF (clone CNTO5048) and isotype-matched control antibodies (clone 
CNTO1322) were provided by D. Shealy (Janssen R&D, Raritan, NJ). Mouse 
TNF was obtained from PeproTech.
Cell culture. PBECs of mice were cultured as described previously (Ridder 
et al., 2011). bEnd.3 cells (ATCC) were grown in DMEM containing FCS 
(10%), glucose (4.5 g/liter), penicillin (100 IU/ml), streptomycin (100 µg/ml), 
and l-glutamine (2 mM). Cell death was measured using the Cytotoxicity 
Detection kit (LDH; Roche) according to the manufacturer´s instructions.
Western blotting. If not indicated otherwise, the cerebellum was homog-
enized in cell lysis buffer (Cell Signaling Technology) supplemented with 
tamoxifen treatment. We did not exclude mice from analysis unless they 
died before the endpoint was measured. Mice were randomly allocated to 
diet or treatment groups. Investigators were blinded for treatment or geno-
type of mice or both in all experiments and analyses.
Histological quantifications. We perfused mice with PBS containing 
heparin (10 IU/ml) to minimize vascular Ig staining. To quantify endoge-
nous Ig extravasation, cryosections were stained with Cy3-labeled donkey 
anti-mouse IgM antibodies upon methanol fixation. The intensity of two 
to four pictures per mouse was determined with ImageJ software (National 
Institutes of Health) and values were expressed relative to control animals. 
The same procedure was used to determine GFAP in cortical tissue stained 
with anti-GFAP antibodies. String vessels were defined as empty basement 
membrane tubes and quantified by measuring the length of collagen IV–positive 
and CD31-negative vessels with ImageJ software. Vessel length was mea-
sured in anti-CD31–stained sections. Two to four images were taken in the 
cortex if not stated otherwise, and analyzed for all parameters. To detect string 
vessels in human paraffin-embedded brain samples, we performed antigen-
retrieval procedures before staining and used anti–collagen IV and anti-CD34, an 
endothelial cell marker. The Ethics Committee of the University of Lübeck 
was informed about the study.
For quantifying 4-HNE- or active caspase 3–positive vessels, cryosec-
tions were stained with anti–4-HNE or anti-active caspase 3 and CD31. 
Measurements were performed as described for string vessels.
Stainings for CD31, collagen IV, pan-laminin, laminin 5, and SMA 
were quantified in a partially automated manner using a custom macro im-
plemented into the image analysis software Fiji. In brief, images were thres-
holded using an auto-threshold method, despeckled, and smoothened to 
remove staining artifacts. After conversion into a binary image, staining 
length was quantified with the Skeleton 2D/3D plugin yielding the number 
and length of stained structures in each image. To ensure reliable quantifica-
tion, the macro was initially compared with a manually quantified dataset 
showing a significant correlation (r2 = 0.9157; unpublished data).
For the quantification of tight junction proteins (ZO-1, claudin-5, and 
occludin) on histological stainings, double-staining against the protein of in-
terest and CD31 was performed. A selection of the vessel area was created by 
thresholding the CD31-image with an auto-threshold method. The thresh-
olded image was used to create a mask, which then was applied onto the 
image showing the staining for the tight junction protein. The mean inten-
sity was determined for this mask.
The staining for GFP in p65Fl and p65beKO mice was performed on 100-µm 
vibratome slices after short perfusion of the animals with 4% paraformalde-
hyde without post-fixation. Sections from one experiment were always 
stained in parallel; images were generated at the same magnification, fluor-
escence excitation intensity, and gain.
Biotin angiography. Mice were i.v. injected with sulfo-NHS-LC-biotin 
(EZ-Link; 5 mg/100 µl per mouse; Thermo Fisher Scientific). 60 min later, 
mice were perfused with PBS and killed. The biotin was labeled on cryosec-
tions with Alexa Fluor 488–coupled Streptavidin (1:1,000; Invitrogen).
Determination of brain water content and BBB permeability. After 
dissection, brains were weighed immediately and dried for 4 d at 85°C. The 
percentage of water content was calculated as (wet weight  dry weight) × 
100/wet weight.
To investigate the permeability to sodium fluorescein, mice were in-
jected i.v. with sodium fluorescein (6 mg/ml dissolved in PBS, 200 µl per 
25 g body weight; Schoch et al., 2002). 30 min later, anesthetized mice were 
transcardially perfused with 10 ml of ice-cold Ringer´s solution. Forebrain 
and cerebellum were homogenized in 0.5 M sodium perborate dissolved in 
dH2O and centrifuged (800 g) for 15 min at 4°C. Ethanol (1.2 ml) was added 
to the supernatant and the samples were again centrifuged (16,100 g) for 20 s 
before measurement of fluorescence in the supernatant.
Dextrans of various sizes labeled with FITC (BD) were suspended in PBS 
(4 and 70 kD, 12 mg/ml; 150 and 2,000 kD, 24 mg/ml; Carman et al., 2011) 
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Vector Biolabs) in medium with reduced (2%) serum concentration for 30 h, 
subsequently incubated in serum-free medium for 18 h, and stimulated with 
murine TNF (10 ng/ml) for 4 h. Cells were then washed once with PBS and 
harvested in glycylglycine buffer (25 mM glycylglycine, 15 mM MgSO4, and 
4 mM EDTA) containing 1% Triton X-100 and 1 mM DTT. Luciferin so-
lution (50 µl; 1 µM d-luciferin [Sigma-Aldrich] in glycylglycine buffer con-
taining 10 µM DTT) and 92 µl assay buffer (16.3 mM KH2PO4, 1.09 mM 
DTT, 2.17 mM ATP dissolved in glycylglycine buffer) were added to 25 µl 
of cell lysate. Firefly luciferase activity was determined with a microplate 
reader (Fluostar Optima; BMG Labtech) and normalized to protein content 
measured by Advanced Protein Assay Reagent (Cytoskeleton).
Real-time RT-PCR. RNA was isolated from cerebellum or PBECs by 
using the ABI Prism 6100 Nucleic Acid PrepStation (Applied Bioscience) 
according to the manufacturer’s instructions. RNA (400 ng) was transcribed 
with Moloney Murine Leukemia Virus Reverse transcription and random 
hexamer primers (Promega). The following primers were used for quantita-
tive RT-PCR: Ocln forward, 5-TACTGGTCTCTACGTGGATCAAT-3, 
Ocln reverse, 5-TTCTTCGGGTTTTCACAGCAA-3, PCR product 137 
bp; Ppia forward, 5-AGGTCCTGGCATCTTGTCCAT-3, Ppia reverse, 
5-GAACCGTTTGTGTTTGGTCCA-3, PCR product 51 bp; Tnf for-
ward, 5-TGTAGCCCACGTCGTAGCAAA-3, Tnf reverse, 5-GCTG-
GCACCACTAGTTGGTTGT-3, PCR product 120 bp; Tnfaip3 forward, 
5-ACAGTGGACCTGAACTTCGC-3, Tnfaip3 reverse, 5-TGCACA-
GGGATCTCCATCAC-3, PCR product 151 bp. Quantitative RT-PCR 
was performed according to the following protocol: 2 min at 50°C, 2 min at 
95°C, 15 s at 95°C, and 1 min at 60°C (40 cycles). Amplification was quanti-
fied using Platinum SYBR Green qPCR SuperMix (Invitrogen). Quantified 
results were normalized to Ppia using the Ct method.
Cerebrovascular reactivity. Cerebrovascular dilatory and contractile func-
tion was tested in vitro in isolated, cannulated, and pressurized (60 mm Hg) 
segments of the PCA isolated from NemobeKO or NemoFl mice. We used on-
line video microscopy to monitor diameter changes (Tong et al., 2005, 
2012). Concentration-dependent dilations to ACh (Sigma-Aldrich) were 
tested on vessels preconstricted with phenylephrine (200 nM; Sigma-Aldrich). 
The contractile response to endothelin-1 (American Peptide) was tested on 
vessels at resting tone as was the tonic production of nitric oxide (NO) mea-
sured by superfusion with the NO synthase inhibitor N-nitro-L-arginine 
(L-NNA; 10 µM, 40 min; Sigma-Aldrich). Because TRPV4 channels are 
involved in the ACh-induced dilation of cerebral arteries (Zhang et al., 
2013), their function was tested in preconstricted vessels with the TRPV4 
selective agonist GSK1016790A. The dilatory capacity of the vessels was 
verified with the NO donor sodium nitroprusside. Reversibility of the vas-
cular deficits in response to ACh was tested before and after preincubation 
(30–60 min) of the arterial segments with the antioxidant butylated hydoxy-
anisole (BHA, 100 µM).
Electron microscopy. For electron microscopy, Tak1Fl and Tak1beKO mice 
were transcardially perfused with 2.5% glutaraldehyde (Paesel and Lorei) in 
0.1 M cacodylate buffer (pH 7.4). Brains were isolated and postfixed in 2.5% 
glutaraldehyde for 2–4 h, and then stored in cacodylate buffer. Brain cortices 
were cut into small pieces and washed once with 0.1 M cacodylate buffer. 
The specimens were postfixed in 1% OsO4 in cacodylate buffer for 1 h and 
dehydrated in ascending series of ethanol and propylene oxide. For contrast 
enhancement, they were bloc stained in uranyl acetate in 70% ethanol for 
4 h and flat-embedded in Araldite (Serva). Using an ultramicrotome (Ultracut R; 
Leica), semithin (1 µm) and ultrathin (50 nm) sections were cut. Ultrathin 
sections were stained with lead citrate, mounted on copper grids, and finally 
analyzed with an EM 10 electron microscope (Carl Zeiss).
Laser doppler flowmetry (LDF). LDF measurements of cerebral blood 
flow were performed as described previously (Tong et al., 2009). Mice were 
anesthetized with ketamine (85 mg/kg, i.m.) and xylazine (3 mg/kg, i.m.) 
and placed in a stereotaxic frame on a heating blanket to maintain a stable 
0.5 M PMSF directly before use. PBECs were cultured on 6-well plates and 
lysed in hot 2× Laemmli buffer, incubated at 95°C for 5 min, and then 
loaded on SDS-PAGE gels. Proteins were transferred to nitrocellulose mem-
branes, which were then incubated with the indicated primary antibodies 
overnight at 4°C and, subsequently, with HRP-conjugated secondary anti-
bodies for 1–2 h at room temperature. For detection, we applied enhanced 
chemiluminescence (SuperSignal West Femto Substrate; Thermo Fisher Scien-
tific) and a digital detection system (GelDoc 2000; Bio-Rad Laboratories).
In vivo MRI acquisition. Mice were anesthetized with an induction dose 
of 4–5% sevoflurane and secured in an MRI-compatible bed. All MRI stud-
ies were performed under 2.5–3% sevoflurane in medical air and animals 
were allowed to breathe spontaneously. Respiration rate and body tempera-
ture was continuously monitored using an MRI-compatible system (Small 
Animal Instruments Inc.), and the temperature was maintained at 37 ± 0.2°C 
throughout the study using a feedback-regulated warming system (Small 
Animal Instruments Inc.).
All MR images were acquired on a 7 T Bruker Pharmascan system 
(Bruker Biospin) using a 28-mm inner-diameter, quadrature volume resona-
tor (RAPID MR International) and using previously established methods 
(Grand’Maison et al., 2013; Hébert et al., 2013). In brief, after the acquisition 
of scout images, ROI-based shimming (MAPSHIM; Bruker Biospin) was 
performed to increase the magnetic field homogeneity within the brain. An-
atomical images were acquired using a 3D balanced Steady-State Free Preces-
sion (b-SSFP) sequence with matrix size = 128 × 128 × 64, field-of-view = 
1.8 × 1.8 × 0.9 cm, spatial resolution = 140 × 140 ×140 µm, number of 
phase-cycles = 4, and number of averages = 4. The phase-cycled images 
were combined using the sum-of-squares reconstruction method to mini-
mize banding artifacts (Bangerter et al., 2004). Perfusion images were ac-
quired with a customized, 3D pseudocontinuous arterial spin labeling (ASL) 
sequence with matrix size = 64 × 64 × 32, field-of-view = 1.8 × 1.8 × 0.9 
cm, spatial resolution = 280 × 280 × 280 µm, and 48 averages. Perfusion la-
beling was achieved by positioning a 2-mm-thick inversion slab in the neck 
region (7 mm inferior to the level of the brainstem) and inverting inflow-
ing blood within this slab every 14 ms using spatially selective sinc radiofre-
quency pulses. The entire scanning session lasted 2.5 h per animal.
MRI processing. An unbiased, symmetric, customized template was gener-
ated from anatomical scans from the 25 mice using an iterative process (Lau 
et al., 2008; Fonov et al., 2011). Before template generation, each recon-
structed image volume underwent image nonuniformity correction using the 
N3 algorithm (Sled et al., 1998), brain masking, and linear spatial normaliza-
tion using a 12-parameter affine transformation (Collins et al., 1994) to map 
individual images from native coordinate space to reference space. In brief, 
the template-generation process involved an iterative (coarse-to-fine resolu-
tion) estimation of the nonlinear transformation to match each MRI scan to 
the evolving average of the population. The final anatomical template (popu-
lation average) was generated with an isotropic voxel resolution of 0.06 mm. 
This customized template was parcellated into an atlas consisting of the whole 
cortex, the hippocampus, and the lateral ventricles using the Montreal Neu-
rological Institute (MNI) McConnell Brain Imaging Centre DISPLAY soft-
ware package. The mask of the cortex was projected onto a standardized 
cortical surface template.
The control perfusion images were linearly registered to the anatomical 
images for each mouse to compensate for potential, slight movement during 
the scanning session. Parametric perfusion maps based on the fractional ASL 
signal, defined as the ratio between the difference [control – labeled] and 
control images (Hébert et al., 2013), were calculated on a voxel-by-voxel 
basis. The perfusion maps were spatially normalized to reference space using 
the transformations derived from the anatomical image registration. The 
individual, spatially normalized perfusion maps were averaged to produce 
group-mean parametric maps. ROI-based perfusion measures were derived 
using the MRI atlas in reference space.
NF-B luciferase assay. After 5 d in vitro, PBECs were infected with 
an adenovirus carrying a NF-B luciferase reporter gene (Ad-NFKb-Luc; 
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(10 cm diameter and 11 cm high) in which stranger mice may be present (see 
below). Two cameras mounted above the setup transferred images to a PC 
with ANY-mazeVideo Tracking System software (Stoelting). Testing com-
prised two trials: acclimation trial and sociability trial. During acclimation, 
the test mouse was placed in the central compartment for 5 min. Divider 
doors were closed so that the mouse did not have access to the left or right 
chamber. During the sociability trial, a stranger mouse was placed into the 
wire cup in either the left or right chamber. Divider doors were opened and 
the test mouse could freely explore all three chambers. After a 10-min ob-
servation period, the test mouse was gently guided toward the central com-
partment and the divider doors were closed again. Preferential exploration 
of the stranger mouse over the empty cup was recorded and analyzed. 
Approaching and spending time within 3 cm of the cup were used to mea-
sure exploratory behavior. Stranger mice were female C57BL/6J mice 
that were group-housed and that had served as stranger mice in other socia-
bility experiments.
Anxiety-related exploration was measured in an elevated plus maze, 
which mice could freely explore for 10 min. The arena consisted of a plus-
shaped maze with two arms (5 cm wide) closed by side walls and two arms 
without walls. Four IR beams recording open and closed arm entries and 
one recording the percentage of time per min spent in the open arms were 
connected to a computerized activity logger. Overall activity was expressed 
as total counts of entries.
For open field recordings, mice were placed in an illuminated square 
arena (47 × 47 cm, 160 lux) and video-recorded for 10 min at the indicated 
time points after tamoxifen injection. Mice were measured during their ac-
tivity phase (dark phase). Inner zone was centered and defined as 36% of the 
overall area. The software ANY-maze was used to analyze the percentage of 
time spent in the inner zone representing a parameter related to anxiety.
Statistical analysis. Based on data from previous projects or from prelimi-
nary experiments, we calculated the sample size for key experiments to 
ensure adequate power to detect prespecified effect sizes. All values are ex-
pressed as means ± SEM. Differences were considered to be significant at 
P < 0.05. If distribution was not normal (Kolmogorov-Smirnov test in Prism 
[GraphPad]), we used either the nonparametric Mann-Whitney or Kruskal-
Wallis test. In other cases, we used the two-sided Student’s t test or ANOVA 
as indicated in the figure legends. Post-hoc tests were only performed if the 
ANOVA or Kruskal-Wallis test showed a significant difference. For statisti-
cal analysis of MRI data, measurements from the left and right hemispheres 
were combined for the ROI analysis to maximize statistical power.
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body temperature (37°C). The skull over the barrel cortex was thinned to 
translucency for the placing of the LDF probe. Contralateral cerebral blood 
flow was recorded and averaged (4–6 stimulations every 30–40 s) before, 
during, and after unilateral whisker stimulation (20 s at 8–10 Hz). Stimulus-
evoked blood flow was expressed as percent change relative to baseline. 
All experiments were completed in less than 20 min, during which time 
mouse blood pressure, blood gases, and pH were physiologically stable 
(Tong et al., 2012).
Local field potential recordings. Mice were anaesthetized with ketamine 
(70 mg/kg, i.p.) and xylazine (14 mg/kg, i.p.) and placed on a heating blan-
ket for maintaining body temperature at 37°C. Two holes were drilled to 
place the electrodes, one over the cerebellum for the reference electrode and 
a second one over the barrel cortex for the recording electrode (Tungsten 
microelectrodes; FHC). The whisker pad was stimulated electrically by in-
troducing two electrodes into the whisker pad. A stimulator (multichannel 
system) was used to create a stimulus with the following parameters: 25 con-
secutive bipolar pulses (0.75 mA, 1 ms duration, 5 Hz). These parameters led 
to a reproducible blood flow response in the contralateral barrel cortex. 
Local field potentials were recorded with an amplifier (2 channels Amplifier 
Model 1800; AM-Systems) and converted into a digital format by an analogue-
digital converter (PowerLab 8/30 ML870; ADInstruments). The software 
LabChart 7 was used to record and to analyze the data (ADInstruments; 
sampling rate 20 kHz; notch filter 50 Hz). For each mouse, four to six 
different areas in the barrel cortex were recorded to find the region with 
the highest response upon whisker stimulation. Each region was stimulated 
three times with the stimulation protocol described above. The amplitudes 
of 30 pulses of the region with the highest amplitude were averaged for 
each mouse.
Pupillary reactivity. We measured pupillary reactivity in awake mice. 
Eyes were video recorded with a camera (MV830; Canon), which is sensi-
tive in the dark, starting with an illumination of 1 lux. After taking the base-
line pupillary diameter for some seconds, a lamp was switched on to increase 
the illumination to 500 lux. Again, pupils were video-recorded for some 
seconds to determine minimal pupillary diameter. Diameter was measured 
manually, each mouse was tested twice and values were averaged.
Behavioral tests. The contextual fear conditioning experiment was per-
formed as described previously (Van der Jeugd et al., 2011). The test cham-
ber (26 × 22 × 18 cm high) was made of clear Plexiglas, and the grid floor 
was used to deliver an electric shock using a constant current shocker (MED 
Associates). The test chamber was placed inside a sound attenuated chamber. 
The experimental period comprised 3 d. On the first day, animals were 
placed in the testing chamber and were allowed to acclimate for 5 min. On 
the second day, animals were again placed in the testing chamber and after 
2 min of exploration (baseline score), a buzzer was sounded for 30 s. This 
auditory stimulus, the conditional stimulus, was followed by a 2-s foot shock 
(0.3 mA), the unconditional stimulus. After the shock, mice were allowed to 
explore the chamber once more for 1 min before they received a second 
conditional–unconditional stimulus pairing. Finally, they were allowed to 
explore for another min. Twenty-four h later, on the third and last day, the 
animals were placed in the same context for 5 min exploration (context 
score). After 90 min, the mouse was again placed in the test chamber. Envi-
ronmental and contextual cues were changed: a white paper square insert 
was placed in the chamber to alter its color, and mint extract was used to 
alter the smell. After 3 min of free exploration (preconditional stimulus 
score), the auditory stimulus was delivered for 3 min (conditional stimulus 
score). Freezing behavior was recorded every 10 s during each trial block 
using the standard interval sampling procedure.
Sociability was assessed as described previously (Naert et al., 2013). The 
setup was made of transparent plexiglass and consisted of a central chamber 
(42 × 26 cm) that gave access to a left and right chamber (26 × 26 cm) via 
sliding doors. The left and right chambers contained cylindrical wire cups 
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